
Opinion|Videos|March 21, 2025
Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis
Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
2
KT-621 Produces 98% STAT6 Degradation in AD Patients
3
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
4
Site-Specific MED Variability Guides 308-nm Excimer Laser Dosing
5

















